The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy
Tài liệu tham khảo
Siu, 2018, Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment, Transl Gastroenterol Hepatol, 3, 89, 10.21037/tgh.2018.10.16
Valery, 2018, Projections of primary liver cancer to 2030 in 30 countries worldwide, Hepatology, 67, 600, 10.1002/hep.29498
Zhang, 2021, Efficacy of drug-eluting beads transarterial chemoembolization plus apatinib compared with conventional transarterial chemoembolization plus apatinib in the treatment of unresectable hepatocellular carcinoma, Cancer Manag Res, 13, 5391, 10.2147/CMAR.S314762
Kong, 2012, Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1alpha/VEGFA, PLoS One, 7, e37266, 10.1371/journal.pone.0037266
Wang, 2018, Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study, Onco Targets Ther, 11, 3407, 10.2147/OTT.S161023
Zhao, 2020, A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: a systematic review and meta-analysis, Ann Transl Med, 8, 542, 10.21037/atm.2020.02.125
Deng, 2022, Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy, Ann Med, 54, 803, 10.1080/07853890.2022.2048416
Xu, 2021, Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial, Clin Cancer Res, 27, 1003, 10.1158/1078-0432.CCR-20-2571
Schmittnaegel, 2017, Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade, Sci Transl Med, 9, 10.1126/scitranslmed.aak9670
Allen, 2017, Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation, Sci Transl Med, 9, 10.1126/scitranslmed.aak9679
Ren, 2022, Efficacy of drug-eluting beads transarterial chemoembolization plus camrelizumab compared with conventional transarterial chemoembolization plus camrelizumab for unresectable hepatocellular carcinoma, Cancer Control, 29, 10.1177/10732748221076806
2020, Guidelines for diagnosis and treatment of primary liver cancer in China, 33
Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin Liver Dis, 30, 52, 10.1055/s-0030-1247132
de la Torre-Alaez, 2020, The pattern of progression defines post-progression survival in patients with hepatocellular carcinoma treated with SIRT, Cardiovasc Intervent Radiol, 43, 1165, 10.1007/s00270-020-02444-2
Xia, 2022, Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study, Front Oncol, 12, 10.3389/fonc.2022.961394
Koroki, 2021, Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma, Liver Cancer, 10, 473, 10.1159/000515552
Yasui, 2022, Real-world data on ramucirumab therapy including patients who experienced two or more systemic treatments: a multicenter study, Cancers (Basel), 14, 10.3390/cancers14122975
Huang, 2022, Regorafenib combined with PD-1 blockade immunotherapy versus regorafenib as second-line treatment for advanced hepatocellular carcinoma: a multicenter retrospective study, J Hepatocell Carcinoma, 9, 157, 10.2147/JHC.S353956
Mei, 2021, Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial, J Immunother Cancer, 9, 10.1136/jitc-2020-002191
Zhao, 2019, Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer, Cancer Immunol Res, 7, 630, 10.1158/2326-6066.CIR-17-0640
Terme, 2013, VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer, Cancer Res, 73, 539, 10.1158/0008-5472.CAN-12-2325
Montasser, 2021, Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma, Histopathology, 79, 36, 10.1111/his.14317
Guo, 2021, Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma, Oncol Lett, 22, 554, 10.3892/ol.2021.12815